Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5752W HIGH $8.60
Volume
942.22 K
Value Traded
613.76 K
Short % Float
0.24%
-26.24%Week
-20.64%1 Month
-32.58%3 Month
-71.24%6 Month
-99.34%5 Year
-99.34%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
25.84 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
68.60 M
Total Shares
41.21 M
Float Shares
4.96 M
Insiders
82.69%
Institutions
6.24%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
LSB Catalyst Timeline
Dated clinical, regulatory and corporate events for LakeShore Biopharma Co., Ltd
Past FDA Catalysts and PDUFA Decisions
How LSB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | YSJA™ rabies vaccine (simplified four-dose regimen) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D30 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
LakeShore Biopharma Co., Ltd faces pipeline headwinds (30/100), with $224M risk-adjusted pipeline value, led by YS-0N-001 in Cancer (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YS-0N-001 Monoclonal antibodyCompletedNCT03131765 | Cancer | Phase 1 | COMPLETED | 31 | Dec 16, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every LSB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PIKA Rabies Vaccine | rabies virus infection | Phase 3 | 2024-04-09 | RVNA seroconversion rate: twice that of the comparator by Day 7Read More | YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine GAITHERSBURG, Md.Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LSB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0 % | 55.00 K | 54.80 K | -60.98% ( -85.63 K) |
LSB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LSB ranks across every disease it competes in
Competitive Position is a premium feature
See how LSB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLSB News
About LakeShore Biopharma Co., Ltd
BIOPHARMAWATCH ELITE PLUS
Trade the next LSB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime